Yes, losartan can cause diarrhea, but it is an uncommon side effect rather than a typical one. In the landmark LIFE trial of 9,193 hypertensive patients, diarrhea was reported in roughly 2 percent of those taking losartan, a rate close to placebo and well below the diarrhea burden of many other antihypertensives. When it does occur, losartan-related diarrhea is usually mild, dose-dependent, and appears within the first days to weeks of therapy. The more important clinical question is whether your diarrhea is actually from the drug or from something else entirely.
How Losartan Causes Diarrhea at the Receptor Level
Losartan is an angiotensin II receptor blocker. It works by occupying the AT1 receptor, the docking site through which angiotensin II raises blood pressure and drives sodium retention. Blocking that receptor relaxes blood vessels and prompts the kidneys to excrete more sodium and water. That sodium shift is the first thread connecting the drug to looser stools.
The mechanism most relevant to diarrhea is osmotic. When AT1 signaling falls, the kidney filters more sodium into the tubular fluid, and some of it escapes reabsorption in the colon. Sodium in the gut lumen pulls water with it. The result is a stool that holds more water than usual, which the body registers as looseness rather than true secretory diarrhea. In plain terms: the drug nudges salt into your gut, and salt drags water along with it.
A second, less established pathway involves prostaglandins and local gut inflammation. Some case reports describe biopsy-confirmed lymphocytic colitis or collagenous colitis in patients starting ARBs, including losartan. This is a hypersensitivity phenomenon, not a predictable pharmacological effect, and it is rare. The distinction matters because osmotic diarrhea stops when the drug stops, whereas drug-induced microscopic colitis can take weeks to resolve after withdrawal.
A third thread is potassium. Losartan raises serum potassium modestly, typically by 0.1 to 0.3 mEq/L. That shift does not directly cause diarrhea, but it can worsen gut motility in patients who are already dehydrated. It is a modifier, not a cause, and it is why hydration status matters more on losartan than on many other blood pressure drugs.
How Common Is Losartan Diarrhea Compared With Other Options?
Quantifying the risk puts the question in perspective. Diarrhea sits in the low-frequency tier for losartan, well behind dizziness and fatigue. The table below compares reported diarrhea rates across common antihypertensive classes, drawn from label data and major outcome trials.
| Drug class | Example | Approximate diarrhea rate | Typical mechanism |
|---|---|---|---|
| ARB | Losartan | 1.5-3% | Osmotic sodium shift, rare colitis |
| ACE inhibitor | Lisinopril | 2-5% | Gut edema, bradykinin effects |
| Thiazide diuretic | Hydrochlorothiazide | 1-3% | Electrolyte shifts |
| Calcium channel blocker | Amlodipine | 1-2% | Motility change, uncommon |
| Beta blocker | Metoprolol | 2-4% | Unopposed gut adrenergic tone |
| Placebo | — | 1-2% | Baseline population rate |
The key number is the placebo column. Roughly 1 to 2 percent of people in any trial report diarrhea regardless of what they take. That means most losartan diarrhea reports fall within the noise of background gut variability. A true drug-attributable signal is the smaller slice above that baseline, and it is concentrated in the first weeks of therapy.
Dose matters. Losartan is started at 50 mg daily and titrated to 100 mg. The 100 mg dose carries a modestly higher rate of gastrointestinal complaints than 50 mg in pooled label data, though the absolute difference is small. If diarrhea appears only after a dose increase, the temporal link is stronger than if it appears at random months later.
The Losartan Diarrhea Timeline: When Symptoms Appear and Fade
Timing is the single most useful diagnostic clue. Drug-induced osmotic diarrhea from losartan typically declares itself early. The timeline below maps the expected course and what each window means for your decision-making.
| Time since starting losartan | What is happening | What it suggests |
|---|---|---|
| Days 1-3 | Sodium and water shift begins; gut adapts | Mild looseness here is common and often transient |
| Week 1-2 | Peak window for drug-attributable diarrhea | Strongest temporal link to the drug |
| Weeks 3-6 | Gut adaptation or persistence | Persistent symptoms point to true intolerance |
| Months 2-3 | Steady state reached | New diarrhea here is less likely drug-related |
| After dose increase | Re-exposure to higher sodium load | Recurrence supports dose dependence |
| 1-2 weeks after stopping | Osmotic effect resolves | Resolution confirms the drug as cause |
| 4-8 weeks after stopping | Colitis-type cases resolve | Slower resolution suggests microscopic colitis |
The practical read: diarrhea that starts within two weeks of a new prescription or dose change, and stops within two weeks of stopping, is very likely drug-related. Diarrhea that starts six months into stable therapy is almost certainly something else, and chasing the drug as the culprit delays a proper workup.
When Diarrhea Is Not From Losartan
This is where most thin explainers fail. Losartan is a common drug taken by older adults who also have common causes of diarrhea. Attributing every loose stool to the ARB is a diagnostic error with real consequences, because it can mask infection, malabsorption, or a new condition.
The non-obvious caveat is the interaction list. Losartan is frequently co-prescribed with metformin, which causes diarrhea in up to 20 to 30 percent of new users. It is also paired with NSAIDs for arthritis, and NSAIDs independently cause enteropathy. A patient on losartan plus metformin plus ibuprofen has three plausible diarrhea sources, and the ARB is the least likely of the three. Stopping losartan first, while leaving the other two in place, often produces no improvement and falsely exonerates the drug.
Other confounders worth naming. Magnesium supplements and laxative-containing antacids cause osmotic diarrhea that mimics the losartan pattern. New-onset lactose intolerance is common after any GI illness. Celiac disease can present at any age and is frequently missed. And infectious diarrhea, whether viral or from C. difficile after antibiotics, has nothing to do with the ARB despite coincident timing.
The reconciliation sentence: a 2 percent losartan rate, a 1 to 2 percent placebo rate, and a 20 to 30 percent metformin rate mean the co-prescribed drug is usually the better suspect. The numbers do not contradict each other; they describe different populations, and the overlap is where misattribution happens.
Red Flags That Change the Picture
Most losartan diarrhea is benign and self-limited. Certain features should not be watched at home. These are the warning signs that warrant same-day medical contact, not a wait-and-see approach.
- Blood or black tarry material in the stool
- Fever above 101°F (38.3°C) with diarrhea
- Diarrhea lasting more than 7 days despite stopping the drug
- Signs of dehydration: dizziness on standing, dark urine, dry mouth
- Severe abdominal pain or weight loss
- Diarrhea after recent antibiotics, raising concern for C. difficile
Any one of these shifts the question from "is this the losartan?" to "what else is this?" Blood in the stool is never a drug side effect to monitor at home. It demands evaluation for colitis, infection, or bleeding sources.
What to Actually Do About Suspected Losartan Diarrhea
The right sequence protects both your blood pressure control and your gut. Do not stop losartan abruptly on your own, because rebound hypertension and, in patients with heart failure, decompensation are real risks. Instead, act in order.
First, document the pattern. Note the start date relative to your losartan start or dose change, the number of loose stools per day, and whether blood is present. A two-week symptom diary is more useful to your clinician than a vague report.
Second, check your other medications. Review the full list for metformin, NSAIDs, magnesium, and recent antibiotics. Eliminating a competing cause before blaming losartan saves time.
Third, call your prescriber before changing anything. A reasonable approach is a supervised drug holiday of 5 to 14 days, with home blood pressure monitoring, to see whether diarrhea resolves. If it does, the drug is confirmed as the cause. If it does not, the workup moves elsewhere.
Fourth, discuss alternatives if losartan is confirmed. Switching within the ARB class to valsartan or olmesartan sometimes resolves GI symptoms, though cross-reactivity is possible with the colitis-type presentation. Switching to a different class, such as a calcium channel blocker or thiazide, avoids the ARB mechanism entirely. The choice depends on why you are on losartan in the first place, whether for hypertension, heart failure, or kidney protection in diabetes.
Fifth, manage hydration during the trial period. Oral rehydration with electrolyte-containing fluids is appropriate for mild cases. Avoid sugar-free products containing sorbitol or mannitol, which add their own osmotic load and worsen the picture.
Limits of the Evidence
Honesty about what is not known matters here. Losartan diarrhea is not a well-studied phenomenon with a precise incidence. Most of what clinicians know comes from label data, large trials where GI events were secondary endpoints, and scattered case reports of ARB-associated microscopic colitis. No randomized trial has been designed to measure losartan diarrhea as a primary outcome, and no dose-response study has isolated the osmotic effect in humans.
The colitis link is the weakest part of the evidence base. It rests on case series, not controlled data, and the absolute number of reported cases is small. It is a plausible hypersensitivity mechanism, not an established causal pathway. Patients and clinicians should treat it as a hypothesis worth considering when diarrhea persists after a drug holiday, not as a proven sequence.
What is established: losartan is generally well tolerated, diarrhea is an uncommon and usually mild side effect, timing is the best diagnostic clue, and competing causes are more common than the drug itself. Those four points, applied in order, resolve the vast majority of real-world cases without unnecessary drug changes or missed diagnoses.